Skip to main content
    X

    X4 Pharmaceuticals Inc (XFOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.83
    -0.29 (-9.29%)

    Market Cap: $318.59M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    X4 Pharmaceuticals Inc (XFOR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to X4 Pharmaceuticals are Fulcrum Therapeutics (FULC), Phathom Pharmaceuticals (PHAT) and Bicycle Therapeutics (BCYC). By market cap, X4 Pharmaceuticals ranks 8th of the 13 companies on this page; Phathom Pharmaceuticals (PHAT) is the largest at $492.63M.

    Peer Comparison

    XFOR's ROIC of -36.9% is below the peer median of -2.3%, and its revenue growth of 63.1% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    X4 Pharmaceuticals (XFOR)$318.59MN/A21.7x0.0%-36.9%63.1%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Shattuck Labs Inc (STTK)$473.57MN/AN/A0.0%N/A-66.6%0.00%
    Bright Minds Biosciences Inc (DRUG)$227.96MN/AN/A0.0%-11.2%0.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Larimar Therapeutics Inc (LRMR)$313.73MN/AN/A0.0%N/A0.0%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Fennec Pharmaceuticals Inc (FENC)$410.25M159.5x6.8x3.0%N/A57.3%0.00%
    Peer median$362.09M82.9x4.7x0.0%-2.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to X4 Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Shattuck Labs Inc (STTK)
    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States.
    STTK competitors
    Bright Minds Biosciences Inc (DRUG)
    Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies...
    DRUG competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Larimar Therapeutics Inc (LRMR)
    Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases.
    LRMR competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    Fennec Pharmaceuticals Inc (FENC)
    Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States.
    FENC competitors

    Frequently Asked Questions About XFOR

    Who are X4 Pharmaceuticals' main competitors?

    The companies most similar to X4 Pharmaceuticals include Fulcrum Therapeutics (FULC), Phathom Pharmaceuticals (PHAT), Bicycle Therapeutics (BCYC), Rocket Pharmaceuticals (RCKT) and Shattuck Labs (STTK), listed from the closest match.

    Who is X4 Pharmaceuticals' biggest competitor?

    Phathom Pharmaceuticals (PHAT) is the largest of the similar companies at $492.63M; Fulcrum Therapeutics (FULC) is the closest match by business profile, size, sector and industry.

    How does XFOR stock compare with its competitors?

    XFOR's P/S is 21.7x against a peer median of 4.7x; its net margin is 0.0% against a peer median of 0.0%.

    Which of X4 Pharmaceuticals' competitors pays a higher dividend?

    X4 Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is X4 Pharmaceuticals bigger than its competitors?

    No. X4 Pharmaceuticals is 8th by market cap among the 13 companies on this page; the largest is Phathom Pharmaceuticals (PHAT) at $492.63M.